Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia
Keywords: 
FDG-PET
Primary progressive aphasia
PPA
Neurodegenerative
Semantic
Logopenic
Agrammatic
Dementia
Issue Date: 
2018
Publisher: 
Springer
ISSN: 
1619-7070
Note: 
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Citation: 
Bouwman, F. (Femke); Orini, S. (Stefania); Gandolfo, F. (Federica); et al. "Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia". European journal of nuclear medicine and molecular imaging. 45 (9), 2018, 1526 - 1533
Abstract
Purpose A joint effort of the European Association of Nuclear Medicine (EANM) and the European Academy of Neurology (EAN) aims at clinical guidance for the use of FDG-PET in neurodegenerative diseases. This paper addresses the diagnostic utility of FDG-PET over clinical/neuropsychological assessment in the differentiation of the three forms of primary progressive aphasia (PPA). Methods Seven panelists were appointed by the EANM and EAN and a literature search was performed by using harmonized PICO (Population, Intervention, Comparison, Outcome) question keywords. The studies were screened for eligibility, and data extracted to assess their methodological quality. Critical outcomes were accuracy indices in differentiating different PPA clinical forms. Subsequently Delphi rounds were held with the extracted data and quality assessment to reach a consensus based on both literature and expert opinion. Results Critical outcomes for this PICO were available in four of the examined papers. The level of formal evidence supporting clinical utility of FDG-PET in differentiating among PPA variants was considered as poor. However, the consensual recommendation was defined on Delphi round I, with six out of seven panelists supporting clinical use. Conclusions Quantitative evidence demonstrating utility or lack thereof is still missing. Panelists decided consistently to provide interim support for clinical use based on the fact that a typical atrophy or metabolic pattern is needed for PPA according to the diagnostic criteria, and the synaptic failure detected by FDG-PET is an earlier phenomenon than atrophy. Also, a normal FDGPET points to a non-neurodegenerative cause.

Files in This Item:
Thumbnail
File
s00259-018-4034-z.pdf
Description
Size
560.23 kB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.